Walleye Trading
NTLA icon

Walleye Trading’s Intellia Therapeutics NTLA Stock Holding History

Walleye Trading’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,600
Closed -$203K – 4519
2025
Q4 		$203K Sell
22,600
-80,900
-78% -$1.11M ﹤0.01% 3380
2025
Q3 		$1.79M Sell
103,500
-27,400
-21% -$337K ﹤0.01% 1891
2025
Q2 		$1.23M Buy
130,900
+113,300
+644% +$930K ﹤0.01% 2056
2025
Q1 		$125K Buy
+17,600
New +$178K ﹤0.01% 3291
2024
Q3 		– Sell
-50,500
Closed -$1.13M – 4440
2024
Q2 		$1.13M Buy
50,500
+47,100
+1,385% +$1.12M ﹤0.01% 1981
2024
Q1 		$93.5K Sell
3,400
-8,700
-72% -$242K ﹤0.01% 3802
2023
Q4 		$369K Sell
12,100
-1,200
-9% -$34.5K ﹤0.01% 3333
2023
Q3 		$421K Sell
13,300
-19,400
-59% -$753K ﹤0.01% 3090
2023
Q2 		$1.33M Buy
32,700
+30,000
+1,111% +$1.22M ﹤0.01% 1946
2023
Q1 		$101K Sell
2,700
-4,300
-61% -$169K ﹤0.01% 3854
2022
Q4 		$244K Sell
7,000
-8,800
-56% -$418K ﹤0.01% 3418
2022
Q3 		$884K Buy
15,800
+1,000
+7% +$62K ﹤0.01% 2354
2022
Q2 		$766K Buy
14,800
+300
+2% +$15.2K ﹤0.01% 2493
2022
Q1 		$1.05M Buy
14,500
+100
+0.7% +$8.47K ﹤0.01% 2186
2021
Q4 		$1.7M Sell
14,400
-3,200
-18% -$401K 0.01% 1772
2021
Q3 		$2.36M Buy
17,600
+6,500
+59% +$984K 0.01% 1474
2021
Q2 		$1.8M Buy
11,100
+1,100
+11% +$85.7K 0.01% 1590
2021
Q1 		$803K Buy
+10,000
New +$671K ﹤0.01% 2131
2020
Q1 		– Sell
-19,700
Closed -$289K – 4369
2019
Q4 		$289K Buy
+19,700
New +$274K ﹤0.01% 2855
2019
Q2 		– Sell
-26,400
Closed -$451K – 4349
2019
Q1 		$451K Buy
26,400
+15,100
+134% +$225K ﹤0.01% 2358
2018
Q4 		$154K Buy
11,300
+6,600
+140% +$123K ﹤0.01% 3619
2018
Q3 		$135K Sell
4,700
-40,700
-90% -$1.18M ﹤0.01% 4032
2018
Q2 		$1.24M Buy
45,400
+31,300
+222% +$758K 0.01% 1869
2018
Q1 		$297K Buy
14,100
+9,200
+188% +$226K ﹤0.01% 3144
2017
Q4 		$94 Buy
+4,900
New +$113K ﹤0.01% 3857

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Walleye Trading's NTLA Position: Q1 2026 in Review

Walleye Trading sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 11,663 shares — an estimated $105K sold.

Walleye Trading first reported a position in NTLA in Q4 2017 and held it in 13 quarters. The position peaked at $5.14M in Q2 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Walleye Trading reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Trading sold 11,663 Intellia Therapeutics shares in Q1 2026, an estimated $105K.
  • Walleye Trading first reported a position in Intellia Therapeutics in Q4 2017 and held it in 13 quarters.
  • Walleye Trading's Intellia Therapeutics position peaked at $5.14M in Q2 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.